June 17th 2021
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
November 18th 2014
June 13th 2013
June 12th 2013
Congressional coalition rallies against CMS ban on pharmacy home deliveries of diabetes testing suppliesJune 4th 2013
Forty-three members of Congress are urging the Centers for Medicare and Medicaid Services (CMS) not to implement a new policy that prohibits independent community pharmacies from providing same-day, home delivery of diabetes testing supplies (DTS) to homebound seniors.
Disinfecting all ICU patients significantly reduces MRSAMay 30th 2013
Decolonization of all intensive care unit (ICU) patients with antimicrobial soap and ointment significantly reduces all bloodstream infections, including methicillin-resistant Staphylococcus aureus (MRSA), according to a study published in the New England Journal of Medicine.
Managed care approach to substance abuse treatmentMay 20th 2013
An examination of people’s behaviors as they relate to drug use in the 20th century has shown that people will expend a large amount of energy to acquire any agent that has the ability to alter their minds, bodies, or behaviors in order to achieve a euphoric effect.
Guideline recommendations issued for molecular testing, targeted therapies in lung cancerApril 8th 2013
The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) recently issued evidence-based guidelines on molecular testing in lung cancer, and support the recommendation that physicians conduct testing in advanced non-small cell lung cancer patients at the time of diagnosis or at the time of recurrence or progression.
Patients who adhere to statin regimens are healthier, but higher drug spending makes overall care more costlyFebruary 28th 2013
Individuals with high cholesterol who stay on their statin medications over a 2-year period are healthier than comparable nonadherent individuals, but the overall cost of their care is slightly higher, according to a new study.
Recent FDA action (through February 2013) related to, rintatolimod, insulin degludec, insulin degludec/insulin aspart, dolutegravir, Radium-223 dichloride, APG101, LG631-CD34, Placental eXpanded, buprenorphine hydrochloride, naloxone HCI dihydrate, doxorubicin hydrochloride, clindamycin in 5% dextrose, Adderall
FDA Actions in Brief February 2013February 28th 2013
Recent FDA Approvals (through February 2013) related to (Ado-trastuzumab, Kadcyla, Genentech, Everolimus, Zortress, Novartis, Adapalene, benzoyl peroxide, Epiquo, Galderma, pomalidomide, Pomalyst, Celgene, alogliptin, Nesina, Takeda Pharmaceuticals, Kazano, Oseni, imatinib, Gleevec, mesalamine, Delzicol, Warner Chilcott, mipomersen sodium, Kynamro, Genzyme, Isis Pharmaceuticals, Merck, Oxutrol for Women, glycerol phenylbutyrate, Ravicti, Hyperion Therapeutics, pneumococcal 13-valent Conjugate Vaccine, Prevnar 13, Pfizer
Low-dose contraceptive patch comparable to combination oral contraceptive in safety, tolerability studyFebruary 28th 2013
A low-dose contraceptive patch is comparable to combination oral contraceptive in a comparative study, according to phase 3 data presented at the American College of Obstetricians and Gynecologists' (ACOG) 60th Annual Clinical Meeting.
An update in attention deficit/hyperactivity disorderFebruary 28th 2013
Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder in children. New formulations of stimulants and nonstimulants allow for individualization of therapy for patients to receive the maximum benefit while minimizing side effects.
Community-based intervention can help reduce mortality from opioid overdoseFebruary 28th 2013
In the study of communities in Massachusetts with high numbers of opioid overdose deaths, implementation of overdose education and naloxone distribution (OEND) were associated with a significant reduction in opioid overdose death rates.
From the American College of Gastroenterology Annual Scientific Meeting: Know your options for cost-effective management of HEFebruary 28th 2013
The economic implications of HE are numerous and marked altered as based upon direct and indirect costs, worsening of patient's and patient's family members quality of life, employment status, and autonomy.
From the American Academy of Ophthalmology Annual Meeting: Anti-VEGF drugs: Not just for retinal pathologies aloneFebruary 28th 2013
Use of anti-vascular endothelial growth factor (VEGF) drugs may be beneficial in patients with neovascular glaucoma and to control complications after filtration surgeries.
Extended dabigatran use reduces risk of recurrent VTE, study findsFebruary 27th 2013
Dabigatran used beyond the initial 3 months of treatment at a dose of 150 mg twice daily reduced the risk of recurrent venous thromboembolism (VTE), according to a study published February 21 in the New England Journal of Medicine.